Merck KGaA (STU:MRKC) Total Long-Term Liabilities: €13,902 Mil (As of Mar. 2026)


STU:MRKC Merck KGaA STU:MRKC
82 GF Score
Price €26.80
GF Value €27.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Merck KGaA Total Long-Term Liabilities?

Merck KGaA STU:MRKC +1.52% 82 Total Long-Term Liabilities is €13,902 Mil as of Mar. 2026. GuruFocus rates STU:MRKC with a GF Score™ of 82/100 and a GF Value™ of €27.71 (Fairly Valued). The stock has 9 warning signs investors should review.

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Merck KGaA's Total Long-Term Liabilities for the quarter that ended in Mar. 2026 was €13,902 Mil.

Merck KGaA Total Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Merck KGaA's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA Total Long-Term Liabilities Chart

Merck KGaA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,514.00 13,016.00 13,041.00 10,312.00 13,825.00

Merck KGaA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,973.00 9,165.00 13,290.00 13,825.00 13,902.00
STU:MRKC
82GF Score
Merck KGaA STU:MRKC
Total Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck KGaA Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

What does a Total Long-Term Liabilities of €13,902 Mil mean?
Merck KGaA (STU:MRKC) has a Total Long-Term Liabilities of €13,902 Mil as of Mar. 2026. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Merck KGaA and its competitors.
Is Merck KGaA's Total Long-Term Liabilities too high?
Merck KGaA's current Total Long-Term Liabilities is €13,902 Mil. Overall, Merck KGaA has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Total Long-Term Liabilities compare to ZTS and UTHR?
Merck KGaA's Total Long-Term Liabilities of €13,902 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Liabilities for a Drug Manufacturers company?
A good Total Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Total Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Liabilities mean?
A high Total Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Toal Long-Term Liabilities is the obiligation expected to be repaid beyond the following twelve months or one business cycle. View historical data on Merck KGaA and its competitors. Merck KGaA's current Total Long-Term Liabilities is €13,902 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (STU:MRKC) is currently considered Fairly Valued. The stock's GF Value™ is €27.71, compared to a current price of €26.80 — trading 3.3% below its estimated fair value. The current Total Long-Term Liabilities is €13,902 Mil. Merck KGaA's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Liabilities calculated?
Total Long-Term Liabilities is calculated from a company's financial statements. For Merck KGaA (STU:MRKC), the current Total Long-Term Liabilities is €13,902 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck KGaA (STU:MRKC) Overvalued in 2026?

Based on GuruFocus' analysis, Merck KGaA stock appears to be undervalued. The current stock price of €26.80 is trading 3.3% below its estimated GF Value™ of €27.71. GuruFocus considers Merck KGaA to be Fairly Valued.

Key valuation signals for STU:MRKC:

  • Total Long-Term Liabilities: €13,902 Mil
  • GF Value™: €27.71 vs. price of €26.80 (3.3% below fair value)
  • GF Score™: 82/100 with 9 warning signs

No single metric tells the full story. See the STU:MRKC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck KGaA Business Description

Address Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
82GF Score

Get the complete analysis for STU:MRKC

Total Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€27.71
GF Value